ABR-238901
CAS No. 1638200-22-2
ABR-238901( —— )
Catalog No. M35093 CAS No. 1638200-22-2
ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 190 | Get Quote |
|
| 5MG | 297 | Get Quote |
|
| 10MG | 472 | Get Quote |
|
| 25MG | 725 | Get Quote |
|
| 50MG | 994 | Get Quote |
|
| 100MG | 1332 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameABR-238901
-
NoteResearch use only, not for human use.
-
Brief DescriptionABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
-
DescriptionABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research.
-
In Vitro——
-
In VivoAnimal Model:C57BL/KaLwRij mice with 5T33MMvv cells Dosage:30 mg/kg Administration:Gavage; daily; for 3 weeks Result:Caused less angiogenesis.Caused less IL6 and IL10 in myeloid-derived suppressor cells (MDSCs).
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetTLR
-
RecptorTLR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1638200-22-2
-
Formula Weight394.63
-
Molecular FormulaC11H9BrClN3O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 33.33 mg/mL (84.46 mM; Ultrasonic (<60°C); H2O : < 0.1 mg/mL (insoluble)
-
SMILESCOc1ncc(cc1Br)S(=O)(=O)Nc1cncc(Cl)c1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5(10):839-846.?
molnova catalog
related products
-
Gardiquimod
Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells.
-
Telratolimod
Telratolimod is a toll-like receptors 7/8 agonist. It has an antitumor activity.
-
CpG ODN 10101
CpG ODN 10101 (CPG 10101) is a novel potent and selective Toll-like receptor 9 (TLR9)-containing oligodeoxynucleotide agonist with antiviral activity for the treatment of chronic infections.
Cart
sales@molnova.com